Dog Aging Project Details Study Design and Cohort Data for 50,188 Companion Dogs
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
The Dog Aging Project has published its study design and baseline cohort data for 50,188 companion dogs, establishing a massive open-access translational dataset to investigate the genetic, multi-omic, and environmental determinants of healthy aging.
What happened
On November 4, 2026, the Dog Aging Project (DAP) published the methodology and rationale for the 'DAP Pack' in the journal GeroScience, detailing the framework of its long-term, prospective, longitudinal, observational study.
As of December 31, 2024, the project enrolled 50,188 companion dogs across all 50 US states, capturing over five years of longitudinal data with 14,978 documented deaths.
The paper described the structures of multiple nested cohorts within the pack, including the Foundation cohort (6,054 dogs), the Precision multi-omic cohort (976 dogs), the Brain Health Study (135 dogs), and the Test of Rapamycin in Aging Dogs (221 dogs).
Owners provided extensive health histories and environmental profiles via the ten-module Health and Life Experience Survey (HLES), which requires approximately 150 minutes to complete, supplemented by annual follow-ups and cognitive-physical assessment activities.
Why it matters
Companion dogs serve as an optimal translational model for human aging because they possess a well-characterized genome, phenotypic variation in lifespan, and share a common physical and social exposome with their human owners.
The DAP platform utilizes an open-science model, allowing the global research community charge-free access to curated annual datasets via the Broad Institute's Terra platform to accelerate geroscience discovery.
With 14,978 documented deaths and a 69% completion rate for its End-of-Life Survey (EOLS), the cohort provides robust endpoints for prospective, longitudinal analyses of canine mortality.
Market impact
The systematic characterization of normative aging trajectories and mortality profiles provides essential baseline parameters that can be used by veterinary biotechnology firms to design clinical trials for dog longevity therapeutics.
The paper's detailed account of owner-reported data limitations—such as a demographic bias toward highly educated, white, and higher-income owners (79.3% holding a Bachelor's degree or higher)—highlights key confounding factors that commercial geroscience developers must account for in real-world evidence strategies.
What comes next
The future release of unblinded clinical results from the Test of Rapamycin in Aging Dogs (TRIAD), a double-blind, placebo-controlled clinical trial evaluating the lifespan, cognitive, and cardiac benefits of rapamycin.
The integration of artificial intelligence models currently under development by the DAP team to enable automated data extraction from uploaded veterinary electronic medical records (VEMRs).
Company relevance
Structured relationships recorded at publication time. Sector exposure is thematic only — it does not mean the company took part. Not market data.
- Loyal
Sector exposure · CLINICAL · REGULATORY · COMMERCIAL
The Dog Aging Project's baseline mortality, health history, and aging trajectory data provide a vital clinical and translational reference framework that directly supports veterinary biotechnology companies focused on dog longevity, such as Loyal. (LONGEFI analysis)
- Tornado Therapeutics
Sector exposure · MECHANISM · CLINICAL
The TRIAD cohort's clinical evaluation of rapamycin to target mTOR and preserve functional health in aging dogs aligns with and provides translational context for developers targeting the mTORC1 pathway to combat immune aging and infections, such as Tornado Therapeutics. (LONGEFI analysis)
Sources
- NCBIPUBMED:LONGEVITY_RESEARCH